Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]